Preferred first-line test to diagnose inherited or acquired factor XIII (FXIII) deficiency. Appropriate for evaluation of patients with a bleeding disorder who present with normal prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count test results. Monitor FXIII therapy and confirm abnormalities detected on FXIII qualitative assay.
Lt. blue (sodium citrate). Refer to Specimen Handling at www.aruplab.com for hemostasis/thrombosis specimen handling guidelines.
Transfer 2 mL platelet-poor plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Serum. EDTA plasma, clotted or hemolyzed specimens.
Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: at -20°C or below: 1 month; Frozen at -70°C or below: 3 months
Factor XIII Activity 69-143%
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|2006183||Factor XIII Activity||27815-0|
- Factor 13
- fibrin stabilizing factor